SCHEMBL25471843

SCHEMBL25471843

CC(=O)N[C@@H](Cc1ccc(OC(C)=O)c(OC(C)=O)c1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.49
ITGA2B P08514 2/20 0.49
LMNA P02545 1/20 0.49
ALOX15 P16050 4/20 0.47
LDHA P00338 1/20 0.46
FPR2 P25090 1/20 0.45
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45
RAB9A P51151 1/20 0.45
CFD P00746 1/20 0.44
PTGS1 P23219 1/20 0.44
CCR5 P51681 1/20 0.43
DRD1 P21728 1/20 0.43
INSR P06213 1/20 0.43
IGF1R P08069 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
ITGB1 P05556 1/20 0.42
ITGA4 P13612 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10425937 0.93 LDHA (0.56) ITGB3ITGA2BLMNAALOX15LDHA
SCHEMBL9405347 0.93 LDHA (0.56) ITGB3ITGA2BLMNAALOX15LDHA
SCHEMBL9819533 0.93 LDHA (0.56) ITGB3ITGA2BLMNAALOX15LDHA
SCHEMBL11684066 0.92 ALOX15 (0.47) ALOX15LDHAFPR2ALDH1A1KDM4E
SCHEMBL13630692 0.89 ALOX15 (0.62) ITGB3ITGA2BLMNAALOX15LDHA
SCHEMBL25188179 0.88 ITGB3 (0.46) ITGB3ITGA2BALOX15LDHAFPR2
SCHEMBL1070435 0.88 ITGB3 (0.46) ITGB3ITGA2BALOX15LDHAFPR2
SCHEMBL23417656 0.88 ALOX15 (0.49) ALOX15ALDH1A1PTGS1DRD1TACR1
Hydrochloric Acid SCHEMBL11454643 0.87 ITGB3 (0.46) ITGB3ITGA2BALOX15LDHAFPR2
SCHEMBL22290251 0.87 HDAC3 (0.44) ALOX15LDHAFPR2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207410-A1 STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF NEURODERM, LTD. (IL) 2024-06-27 US disclosed
US-20230157985-A1 METHODS FOR TREATMENT OF PARKINSON'S DISEASE NEURODERM, LTD. (IL) 2023-05-25 US disclosed
US-20230157985-A1 METHODS FOR TREATMENT OF PARKINSON'S DISEASE NEURODERM, LTD. (IL) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207410-A1 STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF COMT, TH, DDT ITGB3 4534/4885ITGA2B 4447/4885LMNA 4483/4885
US-20230157985-A1 METHODS FOR TREATMENT OF PARKINSON'S DISEASE DDC, DDT, COMT ITGB3 4772/4885ITGA2B 4780/4885LMNA 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.